
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health demonstrates a robust market position with Simparica Trio maintaining over 50% market share, while the rising trajectory of Credelio Quattro is projected to increase from 12.8% in 2025 to an estimated 16.8% by 2026. Additionally, the company has recorded significant year-over-year growth for its Advantage Family and Seresto products, achieving increases of 33% and 28% respectively in the third quarter of 2025, which reflects a sustained positive sales trend. The strategic acquisitions made by Elanco since its spin-off from Eli Lilly, combined with a diverse portfolio across companion and food animals, underpin a favorable outlook for the company's overall financial performance.
Bears say
Elanco Animal Health faces potential near-term earnings growth risks due to refinancing concerns, particularly in light of rising interest rates exemplified by Dentsply Sirona's recent debt offering at 8.375%. Despite a revenue increase of approximately 50%, the company's EBITDA margin has declined by a couple of hundred basis points, signaling concerns over cost management and profitability. Furthermore, while a $28 million EBITDA outperformance was reported in the second quarter, it raises questions regarding the sustainability of such performance in the context of overall financial health and the imminent risks posed by debt refinancing.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares